Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia

British Journal of Pharmacology

Volumn 134, Issue 2, 2001, Pages 343-352

  Richter, A ^a   Hamann, M ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Adenosine; Basal ganglia; Choreoathetosis; Dyskinesia; Dystonia; Movement disorders

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; METHYLXANTHINE DERIVATIVE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSTONIA; FEMALE; HAMSTER; MALE; NONHUMAN; PRIORITY JOURNAL; STRESS; TREATMENT OUTCOME;

EID: 0034770773     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704268     Document Type: Article

References (39)

1. Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens and medial frontal cortex
2. The behavioural and motor consequences of focal lesions of the basal ganglia in man
3. Paroxysmal diskinesias: Clinical features classification
4. The paroxysmal dyskinesias
5. Classification of dystonia
6. The striatopallidal neuron: A main locus for adenosinedopamine interactions in the brain
7. Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat striatoentopeduncular pathway and its modulation of adenosine A1 receptor-mediated mechanism
8. Adenosine-dopamine receptor interactions as an integrative mechanism in the basal ganglia
9. Adenosine-dopamine interactions in the brain
10. Paroxysmal dystonic choreoathetosis linked to chromosome 2q: Clinical analysis and proposed pathophysiology
11. Adenosine, adenosine receptors and the actions of caffeine
12. Nomenclature and classification of purinoceptors
13. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia
14. Integrated events in central dopamine transmission as analysed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia
15. Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia
16. In vivo extracellular electrophysiology of pallidal neurons in dystonic and nondystonic hamsters
17. Development of selective purinoceptor agonists and antagonists
18. Dystonic disorders
19. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
20. Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models
21. The sz mutant hamster: A genetic model of epilepsy or of paroxysmal dystonia?
22. The dystonias
23. Familial paroxysmal dystonic choreoathetosis. Clinical findings in a large Japanese Family and genetic linkage to 2q
24. 2A adenosine receptor antagonists - Future drugs for Parkinson's disease?
25. 2 receptor binding in the genetically dystonic hamster
26. Insight into adenosine receptor function using antisense and gene-knockout approaches
27. Determination of the effects of caffeine and carbamazepine on striatal dopamine by in vivo microdialysis
28. 2A receptors
29. 1 agonists in dopamine denervated rats
30. Therapeutic aspects of kinesigenic paroxysmal choreoathesosis and familial paroxysmal choreoathetosis of the Mount and Reback type
31. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model
32. CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia
33. The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol
34. Behavioural response to pharmacologic manipulation of serotonin receptors in the genetically dystonic hamster
35. Pathology of idiopathic dystonia: Findings from genetic animal models
36. Fine-tuning neuromodulalion by adenosine
37. Mutational and biochemical analysis of dopamine in dystonia
38. 2A receptors
39. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release